Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Key Summary Prices are anticipated to fall 30-50 percent initially, with the potential for deeper cuts of up to 70-75 percent over time Dr Reddy's could be the first generic player among Indian companies to launch in Canada, and Sun Pharma in Brazil The launch of generic semaglutide is projected to boost overall Indian Pharmaceutical Market (IPM) growth by 0.5-1 percent The impending patent expiry of semaglutide drugs, used to treat diabetes and obesity, across India, emerging markets and select regulated markets such as Canada and Brazil, is expected to unlock a huge revenue opportunity, says a report
P., Wadden, T
By engaging all three pathways, it aims to produce greater weight loss than single or dual-hormone treatments
Fierce Pharma [Preprint] Samms RJ et al (2021) GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
This is an important distinction to understand before starting treatment
Even if that's true at high enough oral doses (the evidence is mixed), it's a fundamentally different mechanism from a prescription GLP-1 medicine
